The proposed randomized study is the first to examine the direct and potential causal effects of BPA administration, consistent with the US EPA safe dose, using gold standard measures over several days on skeletal muscle insulin sensitivity and hepatic glucose production; thus, this study will provide much needed randomized controlled experimental evidence as to whether BPA poses any health risk for type 2 diabetes. The gene discussed is INS; the disease is type 2 diabetes mellitus.